Hematopoietic stem cell transplantation positively affects the natural history of cancer in Nijmegen breakage syndrome

• Verfasst von: Wolska-Kusnierz, Beata [VerfasserIn]
• Verfasst von: Greil, Johann [VerfasserIn]
• Titel: Hematopoietic stem cell transplantation positively affects the natural history of cancer in Nijmegen breakage syndrome
• Verf.angabe: Beata Wolska-Kusnierz, Agata Pastorczak, Wojciech Fendler, Anna Wakulinska, Bozena Dembowska-Baginska, Edyta Heropolitanska-Pliszka, Barbara Piątosa, Barbara Pietrucha, Krzysztof Kałwak, Marek Ussowicz, Anna Pieczonka, Katarzyna Drabko, Monika Lejman, Sylwia Koltan, Jolanta Gozdzik, Jan Styczynski, Alina Fedorova, Natalia Miakova, Elena Deripapa, Larysa Kostyuchenko, Zdenka Krenova, Eva Hlavackova, Andrew R. Gennery, Karl-Walter Sykora, Sujal Ghosh, Michael H. Albert, Dmitry Balashov, Mary Eapen, Peter Svec, Markus G. Seidel, Sara S. Kilic, Agnieszka Tomaszewska, Ewa Wiesik-Szewczyk, Alexandra Kreins, Johann Greil, Jochen Buechner, Bendik Lund, Hanna Gregorek, Krystyna Chrzanowska, and Wojciech Mlynarski
• Jahr: 2021
• Jahr des Originals: 2020
• Umfang: 10 S.
• Teil: volume:27
• Teil: year:2021
• Teil: number:2
• Teil: pages:575-584
• Teil: extent:10
• Fussnoten: Published OnlineFirst October 20, 2020 ; Gesehen am 13.04.2021
• Titel Quelle: Enthalten in: Clinical cancer research
• Ort Quelle: Philadelphia, Pa. [u.a.] : AACR, 1995
• Jahr Quelle: 2021
• Band/Heft Quelle: 27(2021), 2, Seite 575-584
• ISSN Quelle: 1557-3265
• DOI: doi:10.1158/1078-0432.CCR-20-2574
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1753979692

Abstract

Purpose: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. - Experimental Design: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. - Results: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7-21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10−5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138-0.162); P < 0.0001]. - Conclusions: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.